Trial
NCT00597597
Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Rush University Medical Center
Collaborators
—
Condition
Metastatic Breast Cancer
Intervention
Erlotinib
Why stopped
not enough patients enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-17